Woman Sues Pfizer After Depo-Provera Use Linked to Brain Tumor Diagnosis

A New York woman has filed a lawsuit against Pfizer, alleging that long-term use of the birth control injection Depo-Provera caused her to develop a serious brain tumor that required surgery and extensive radiation treatment.

The plaintiff, Elizabeth Fleurisma, says she was diagnosed with a lime-sized intracranial meningioma after receiving Depo-Provera injections for nearly eight years. According to the complaint, the non-cancerous tumor pressed against her brain, forcing her to undergo major surgery followed by more than 25 rounds of radiation therapy.
 

What Elizabeth Fleurisma’s Lawsuit Alleges

Court filings state that Fleurisma began using Depo-Provera as a contraceptive in her early twenties. Over time, she allegedly developed neurological symptoms that ultimately led to imaging scans revealing a sizable brain tumor.

Meningiomas form in the membranes surrounding the brain and spinal cord and, while often non-cancerous, can cause serious complications depending on size and location. Fleurisma’s lawsuit claims the tumor dramatically altered her quality of life and required invasive medical intervention.

The complaint alleges that Pfizer knew or should have known that extended exposure to medroxyprogesterone acetate, the active ingredient in Depo-Provera, was associated with increased meningioma risk but failed to timely update U.S. warning labels.
 

Federal Litigation Continues to Grow

Fleurisma’s case joins a rapidly expanding wave of claims consolidated in federal court, where plaintiffs argue that Pfizer delayed updating safety information despite emerging scientific evidence.

These lawsuits focus on the link between high cumulative doses of synthetic progestins and tumor growth in brain tissue. Plaintiffs claim that had they been properly warned, they would have chosen alternative contraceptive options.

Women affected by similar diagnoses are now seeking accountability through the ongoing Depo-Provera brain tumor litigation, which continues to draw national attention as new cases are filed.

Related coverage and eligibility details can be found in the ongoing Depo-Provera brain tumor lawsuit.

Medical Research Behind the Meningioma Risk

Scientific concern over meningiomas linked to hormonal exposure is not new. Multiple studies have examined how long-term exposure to synthetic progesterone compounds may influence tumor development.

A large French population study published in The BMJ found a significantly increased risk of intracranial meningioma among women using high-dose progestins over extended periods.

In addition, France’s national drug regulator previously suspended certain high-dose progestins after identifying elevated tumor risks, prompting renewed scrutiny of similar medications worldwide.
 

FDA Label Change Came in Late 2025

In December 2025, the U.S. Food and Drug Administration approved a label update for Depo-Provera that now includes warnings about the risk of meningiomas. The revision was made at Pfizer’s request, according to regulatory filings.

Health experts note that European regulators had addressed similar concerns years earlier, raising questions about whether U.S. patients were informed soon enough.

Plaintiffs argue that the timing of the warning change is central to their claims, as many women received injections for years before any mention of brain tumor risk appeared on U.S. labeling.
 

Why This Case Is Drawing National Attention

Fleurisma’s lawsuit has gained traction because it reflects broader concerns about transparency, informed consent, and long-term drug safety. Depo-Provera has been widely prescribed for decades, particularly among women seeking low-maintenance birth control options.

Legal filings emphasize that meningiomas may take years to grow large enough to cause symptoms, meaning patients often remain unaware of the risk until significant damage has occurred.

As federal proceedings move forward, courts will evaluate whether Pfizer adequately disclosed known risks and whether delayed warnings exposed patients to preventable harm.
 

What Happens Next

The Depo-Provera MDL continues to expand as more women come forward with similar diagnoses. Plaintiffs are seeking compensation for medical costs, pain and suffering, and long-term health consequences related to brain tumors.

While Pfizer denies wrongdoing, the litigation is expected to play a major role in shaping future pharmaceutical warning standards and contraceptive safety disclosures.

For now, Fleurisma’s case stands as one of the most visible examples of the growing legal and medical scrutiny surrounding Depo-Provera and meningioma risk.